A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension
Phase of Trial: Phase III
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Zolmitriptan (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Amneal Pharmaceuticals; IMPAX Laboratories
- 07 May 2018 According to a Amneal Pharmaceuticals media release, Impax Laboratories has combined its business (merged) with Amneal Pharmaceuticals LLC, to form Amneal Pharmaceuticals Inc.
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.
- 12 Jul 2017 New trial record